A statement from the chief executive of Eli Lilly, John Lechleiter, made it clear that Eli Lilly and Co had not plans to expand on their diabetes drug partnership with Amylin pharmaceuticals by buying the company. Lechleiter made it clear in a Reuters interview that the relationship is working fine as it is.
Together, the two diabetes companies market the widely used diabetes drug Byetta . By the middle of this year the companies are expected to file for a weekly formulation of the injectable diabetes medication .
Rumours had been circulating that the larger pharmaceutical company would purchase the biotech firm. The alliance between the two companies is one of many around the world, where pharmaceutical companies with capital and distribution/sales networks ally with smaller technological companies.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…